Lucid Diagnostics (LUCD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $1.0M, flat sequentially but up over 500% year-over-year, driven by record EsoGuard test volume of 3,147, up 31% sequentially and 44% annually.

• Over 50 high-volume health fair events held, a 60% increase from the prior quarter, including the first large event with upfront contracted payment.

• Direct contracting initiatives with benefit brokers and self-insured entities are gaining traction, aiming for contractually guaranteed revenues.

• Positive clinical data and advocacy efforts, including support from the American Foregut Society, position the company for broader coverage and reimbursement.

• Substantial doubt exists about the ability to continue as a going concern within one year without additional capital or significant revenue growth.

Financial highlights

• Cash at June 30, 2024, was $24.9M; Series B1 convertible preferred financing raised $11.6M in the quarter, with $29.8M raised in preferred stock offerings in 2024.

• Average quarterly cash burn for the trailing four quarters was $10.6M; cash used in operations for the first half of 2024 was $24.1M.

• Non-GAAP loss for Q2 was $9.7M, with non-GAAP OpEx at $10.6M; GAAP net loss attributable to common stockholders was $11.0M, or $(0.23) per share.

• Revenue recognition is based on actual collections due to early reimbursement stage; $976,000 collected in Q2, with 35% from current quarter claims.

• Cost of revenue for Q2 2024 was $1.6M, with gross margin remaining negative.

Outlook and guidance

• Modest quarter-on-quarter growth expected, with potential for choppy results due to lean sales team and event-driven volumes.

• Revenue growth is contingent on expanding insurance reimbursement for EsoGuard and direct contracting with self-insured employers.

• Submission of final clinical data dossier to MolDX for Medicare coverage expected later in 2024, pending publication of BE1 study.

• Aggressive market access strategy targets regional and national payors, especially in biomarker legislation states.